Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Esophageal Cancer Clinical Trial

Official title:

A Pharmacokinetic Study of Larotinib in Subjects With Mild/Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05048368
• Other study ID #: Z650-HI-105
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 30, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: September 2022
• Source: Sunshine Lake Pharma Co., Ltd.
• Contact: Jia Miao, MD
• Phone: +86 18980601806
• Email: miaosiyi1971[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

Description:

A phase I, a single-center, non-randomized, open, single-dose administration study to explore the safety, pharmacokinetics of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects with normal hepatic function. This study is divided into four cohorts, cohort A and cohort C in healthy subjects, cohort B for mild hepatic function impairment participants, cohort D for moderate hepatic function impairment, participants in cohort A and cohort B, group C and group D should be matched in terms of sex, age, and body mass index (BMI). A total of 32 subjects, 8 in each cohort, both male and female, are planned to be enrolled. If a complete PK blood sample is not collected due to subjects' early withdrawal from the study, new subjects will be enrolled to meet the pharmacokinetic parameters that can be evaluated for each cohort of 8 subjects.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• healthy subjects with normal hepatic function (cohorts A and C) :
• 1. Sign the informed consent form before the trial;
• 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight >50 kg (male) or =45 kg (female) at screening. (BMI) : 18-30 kg/m^2, (including critical value) [BMI= weight (kg)/height^2 (m^2)] (BMI matching ±15% with liver dysfunction cohort);
• 3.Must be in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at Screening;
• 4.Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures.
• Subjects with mild/ Moderate hepatic Impairment (cohorts B and D) :
• 1. Sign the informed consent form before the trial.
• 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight >50 kg (male) or =45 kg (female) at screening. (BMI) : 18-30 kg/m^2;
• 3. Must satisfy the criteria for hepatic Impairment as evidenced by a Child-Pugh class of A or B at Screening:Class A; Mild; Child-Pugh score 5-6;Class B; Moderate; Child-Pugh score 7-9
• 4. The liver function status of the subjects was determined to be stable between 1 month before taking the experimental drug and the end of the study, with no significant change.
• 5. Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures.

Exclusion Criteria:

• ALL subjects
• 1. The subject has been diagnosed with acquired immune deficiency syndrome (AIDS), or tests positive for human immunodeficiency virus (HIV).
• 2. Currently suffering from any bleeding disease, such as gastric and duodenal ulcer
• 3. Those who had undergone major surgery within 6 months before the screening period or the surgical incision did not completely heal;
• 4. History of hand foot syndrome;
• 5. Those who have a history of liver cancer or other malignant tumors before signing the informed consent
• 6. Those who have a history of gastrointestinal and renal diseases or surgery that may affect drug absorption, distribution, metabolism and excretion within 6 months before screening, or have diseases that can reduce compliance
• 7. Take any food or beverage products containing alcohol, caffeine, xanthine and grapefruit within 48 hours prior to the first dose.
• 8. The subject has received blood within 1 month, or donated loss of blood over 400 mL within 3 months prior to the screening
• 9. Have a history of alcoholism or positive alcohol breath test during the screening period;
• 10. Those who smoke more than 5 cigarettes a day or habitually use nicotine containing products 3 months before screening
• 11. Those who had a history of drug abuse or used drugs within 2 years before screening or those who were positive for urinary drug screening during the screening period Allergic constitution
• 12. Allergic constitution
• 13. Within 28 days before screening, inhibitors or inducers of CYP3A4, cyp2c8, CYP2C19 and P-gp were used
• 14. Participated in any other intervention clinical trial within 3 months before screening
• 15. Female subjects with positive pregnancy test results or breastfeeding during screening;
• 16. Any other circumstances that the investigator considers unsuitable for participation in this study
• The following exclusion criteria apply only to healthy subjects with normal hepatic

function (cohorts A and C) :

• 17. he subject has evidence of clinically significant cardiovascular, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities.
• 18. The subject tests positive for HBsAg or Hepatitis C antibody
• 19. The subject has used any prescription or nonprescription drugs within 2 weeks prior to the screening.
• The following exclusion criteria apply only to subjects with mild/ Moderate hepatic

Impairment (cohorts B and D) :

• 17. The following exclusion criteria apply only to subjects with liver function

impairment (cohorts B and D) :

• a) ALT>10×ULN;
• b) AST> 10×ULN;
• c) Absolute count of neutrophils <0.75×10^9/L;
• d) PLT<50×10^9/L
• e) HGB<60 g/L
• f) AFP >100 ng/mL; If 20 ng/mL=AFP=100 ng/mL, liver MRI are required to exclude subjects with suspected HCC.
• g) eGFR<60 mL/min/1.73m^2.
• h) Male:QTcF> 450 msec,Female:QTcF>470 msec?
• 18. The subject has any of the following conditions: Diseases affecting bile excretion such as biliary obstruction; Drug induced liver injury; History of liver transplantation; Liver failure, or liver cirrhosis patients with complications such as hepatic encephalopathy, rupture and bleeding of esophageal and gastric varices, etc; Patients with severe or advanced peritoneal effusion or pleural effusion need puncture drainage and albumin supplementation. Patients with hepatorenal syndrome.
• 19. Previous severe esophagogastric varices or previous portosystemic shunt, including transjugular intrahepatic portosystemic shunt (TIPS)
• 20. Cardiovascular events occurred within 6 months before screening
• 21. Those who use prescription drugs, over-the-counter drugs, Chinese herbal medicine or food supplements other than drugs for the treatment of liver function impairment and other accompanying diseases within 14 days before screening;
• 22. Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the Principal Investigator, may interfere with study procedures or participant safety.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Esophageal Cancer

Intervention

Drug:
• Larotinib
Capsules, Oral, 350 mg, single dose, one day

Locations

Country	Name	City	State
China	West China Hospital of Sichuan University	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Sunshine Lake Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Maximum plasma concentration of study drugs	Day 1 to Day 7
Primary	Area Under Curve From 0 to Infinity (AUC0-infinity)	AUC0-infinity represents the area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity	Day 1 to Day 7
Secondary	Adverse Event	New abnormal findings or worsening of baseline conditions were reported as Adverse Events.	Day-7 to Day 14